glp 1 causing gastroparesis Understanding and GLP-1: Medical Explanation Drug-Induced Gastroparesis and Product Liability

Boehringer Ingelheim #Advances #First-in-Class #Triple #Agonist #BI3034701 into Phase II, Expanding Its #Obesity #Pipeline Boehringer Ingelheim continues to strengthen its obesity franchise with the advancement of BI 3034701, a potential first-in-class #GLP-1/ #GIP/ #NPY2 triple receptor agonist, into Phase II clinical developmentfurther expanding its next-generation cardiometabolic pipeline

All experimental protocols were approved by the University of Virginia IACUC on 04/22/2019 (protocol n: 4269)

Beide omzettingen gebruiken het koperbevattende enzym tyrosinase als katalysator

doi: 10.1038/s41590-020-0677-6 64 HisadaRYoshidaNOriteSYKUmedaMBurbanoCScherlingerMet al